Stocksigma LogoStocksigma Logo

Kilitch Drugs Updates Debt-to-Equity Conversion Terms for Material Subsidiary

Kilitch Drugs (India) Limited issued a correction regarding its 22nd Oct'26 board approval to convert up to INR 57.00 crore of outstanding debt and service

Kilitch Drugs Updates Debt-to-Equity Conversion Terms for Material Subsidiary

Kilitch Drugs India Ltd 路 Outcome 路 13 Nov 2026, 12:25 am

Kilitch Drugs Updates Debt-to-Equity Conversion Terms for Material Subsidiary Kilitch Drugs (India) Limited issued a correction regarding its 22nd Oct'26 board approval to convert up to INR 57.00 crore of outstanding debt and service costs into equity of its material subsidiary, Kilitch Estro Biotech PLC. Due to a typographical error, the rectified acquisition price stands at INR 3,413.23 per share (previously INR 3,414), and the revised allotment is 1,66,471 equity shares (previously 1,66,472 shares). All other terms and conditions of the debt conversion remain unchanged.

Original exchange filing (PDF)

More announcements from Kilitch Drugs India Ltd

All Kilitch Drugs India Ltd announcements